OCWP
NTLA icon

Owl Creek Wealth Partners’s Intellia Therapeutics NTLA Stock Holding History

Owl Creek Wealth Partners’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.45K Hold
145
– – ﹤0.01% 1131
2026
Q1 		$1.86K Buy
+145
New +$1.85K ﹤0.01% 1114

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Owl Creek Wealth Partners's NTLA Position: Q2 2026 in Review

Owl Creek Wealth Partners held its Intellia Therapeutics (NTLA) position steady in Q2 2026 at 145 shares worth $2.45K. The position accounts for ﹤0.01% of the portfolio, ranked #1131.

Owl Creek Wealth Partners first reported a position in NTLA in Q1 2026 and has held it in 2 quarters since. 306 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Owl Creek Wealth Partners held 145 shares of Intellia Therapeutics worth $2.45K as of Q2 2026.
  • Owl Creek Wealth Partners left its Intellia Therapeutics share count unchanged in Q2 2026.
  • Intellia Therapeutics made up ﹤0.01% of Owl Creek Wealth Partners's portfolio in Q2 2026, its #1131 holding.
  • Owl Creek Wealth Partners first reported a position in Intellia Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 306 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Owl Creek Wealth Partners's 13F filing for Q2 2026, filed 20 Jul 2026.